Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort
To the Editor: Dermatologic toxicities occur in non-small cell lung cancer (NSCLC) patients treated with targeted therapies and immune checkpoint inhibitors (ICIs) and most frequently in epidermal growth factor receptor inhibitors (EGFRIs), presenting an therapeutic challenge.1 EGFRIs-related rashes were associated with prolonged survival in clinical trials with small datasets.2 However, information is limited on dermatologic toxicities of newer-generation targeted drugs and ICIs in advanced-stage NSCLC, especially under real-world conditions.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Yanmei Peng, Ashok V. Kumar, Zhong Gu, Nikhila Kosuru, Jason A. Wampfler, Pedro A. Reck dos Santos, Nathan Y. Yu, Jonathan D'Cunha, Vinicius Ernani, Collin M. Costello, Ping Yang Tags: Research letter Source Type: research
More News: Academies | Cancer | Cancer & Oncology | Clinical Trials | Dermatology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Toxicology